Expert: The Future of Products Containing Rare Cannabinoids is in Pharmacy
July 22nd 2021Pharmacy Times interviewed Dennis O’Neill, president and board member of BIOMEDICAN, on the outlook around the future of biosynthesis therapeutics that use rare cannabinoids to treat a range of health issues, from mental health disorders to diabetes.
The Reasons Behind Bipartisan Support for Granting Pharmacists Provider Status for Medicare Part B
July 21st 2021Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, outlined what has led to legislation granting pharmacists provider status gaining bipartisan support.
FDA Advisory Committee Members Raise Concerns About Aducanumab
July 21st 2021In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.
An Overview of Pipeline Indications for Current Commercially Approved CAR T Products
July 19th 2021Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, a clinical pharmacy specialist at Penn Medicine in the University of Pennsylvania Health System, and Andrew Lin, PharmD, BCOP, an oncology pharmacy specialist at Memorial Sloan-Kettering Cancer Center, to provide an overview of current CAR T-cell therapies.
What the Data Shows Regarding the Current Role in Therapy of Approved CAR T Products
July 16th 2021Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss their presentation at the recent ATOPP 2021 summit on re-examining the why, who, and where of CAR T therapy.
Expert: Aducanumab Approval Creates Hope, New Opportunities for Patients with Alzheimer Disease
July 16th 2021Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.
The Future of ITP Treatments and Tavalisse
July 14th 2021Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.